40545
document
Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery . STUDY OBJECTIVE To determine the efficacy of transdermal scopolamine in addition to ondansetron in decreasing the incidence of postoperative nausea and vomiting ( PONV ) . DESIGN Randomized controlled trial . SETTING Academic hospital . PATIENTS 126 ASA physical status I and II patients undergoing outpatient plastic surgery with three or more risk factors for PONV . INTERVENTIONS Patients were randomly assigned to one of two groups to receive ( Group 1 ) a transdermal scopolamine ( TDS ) patch or ( Group 2 ) , a placebo patch two hours before surgery . MEASUREMENTS Occurrence of vomiting , severity of nausea using a visual analog scale ( VAS ) , rescue medication , pain intensity and pain medications , and side effects were recorded every hour until discharge from hospital , then every 4 hours thereafter for a total of 24 hours . MAIN RESULTS A statistically significant reduction in postoperative nausea between 8 and 24 hours in patients receiving TDS was noted . CONCLUSIONS Transdermal scopolamine in addition to ondansetron benefits patients at high risk for PONV undergoing outpatient plastic surgery for up to 20 hours after surgery .
40546
Intervention_Pharmacological
Transdermal scopolamine patch
40547
Intervention_Pharmacological
ondansetron
40548
Intervention_Pharmacological
transdermal scopolamine
40549
Intervention_Pharmacological
ondansetron
40550
Intervention_Pharmacological
transdermal scopolamine ( TDS ) patch
40551
Intervention_Control
placebo patch
40552
Intervention_Pharmacological
scopolamine
40553
Outcome_Physical
postoperative nausea and vomiting
40554
Outcome_Physical
Occurrence of vomiting
40555
Outcome_Physical
severity of nausea
40556
Outcome_Physical
visual analog scale ( VAS )
40557
Outcome_Other
rescue medication
40558
Outcome_Pain
pain intensity
40559
Outcome_Other
pain medications
40560
Outcome_Adverse-effects
side effects
40561
Outcome_Physical
postoperative nausea
40562
Participant_Condition
undergoing ambulatory cosmetic surgery .
40563
Participant_Condition
postoperative nausea and vomiting
40564
Participant_Condition
PONV
40565
Participant_Sample-size
126
40566
Participant_Condition
ASA physical status I and II patients undergoing outpatient plastic surgery
40567
Participant_Condition
three or more risk factors for PONV